Marteau Dave, McDonald Rebecca, Patel Kamlesh
Health and Human Development, University of East London, London, UK.
Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
BMJ Open. 2015 May 29;5(5):e007629. doi: 10.1136/bmjopen-2015-007629.
To examine the population-wide overdose risk emerging from the prescription of methadone and buprenorphine for opioid substitution treatment in England and Wales.
Retrospective administrative data study.
National databases for England and Wales.
PARTICIPANTS/CASES: Drug-related mortality data were drawn from the Office for National Statistics, and prescription data for methadone and buprenorphine were obtained from the National Health Service for the years 2007-2012. During this 6-year period, a total of 2366 methadone-related deaths and 52 buprenorphine-related deaths were registered, corresponding to 17,333,163 methadone and 2,602,374 buprenorphine prescriptions issued. The analysis encompassed poisoning deaths among members of the wider population of England and Wales who consumed, but were not prescribed these medications, in addition to patients prescribed methadone or buprenorphine.
Mortality risk: substance-specific overdose rate per 1000 prescriptions issued; relative risk ratio of methadone in relation to buprenorphine.
During the years 2007-2012, the pooled overdose death rate was 0.137/1000 prescriptions of methadone, compared to 0.022/1000 prescriptions of buprenorphine (including buprenorphine-naloxone). The analysis generated a relative risk ratio of 6.23 (95% CI 4.79 to 8.10) of methadone in relation to buprenorphine. UK Borders Agency data were taken into consideration and revealed that only negligible amounts of methadone and buprenorphine were seized on entering UK territory between 2007 and 2012, suggesting domestic diversion.
Our analysis of the relative safety of buprenorphine and methadone for opioid substitution treatment reveals that buprenorphine is six times safer than methadone with regard to overdose risk among the general population. Clinicians should be aware of the increased risk of prescribing methadone, and tighter regulations are needed to prevent its diversion.
研究在英格兰和威尔士,用于阿片类药物替代治疗的美沙酮和丁丙诺啡处方所产生的全人群过量用药风险。
回顾性行政数据研究。
英格兰和威尔士的国家数据库。
参与者/病例:药物相关死亡率数据来自英国国家统计局,美沙酮和丁丙诺啡的处方数据来自国民医疗服务体系2007年至2012年的数据。在这6年期间,共登记了2366例与美沙酮相关的死亡和52例与丁丙诺啡相关的死亡,对应开出了17333163份美沙酮处方和2602374份丁丙诺啡处方。分析涵盖了英格兰和威尔士更广泛人群中使用但未被处方这些药物的人群以及开具美沙酮或丁丙诺啡处方的患者中的中毒死亡情况。
死亡率风险:每开出1000份处方的特定物质过量率;美沙酮相对于丁丙诺啡的相对风险比。
在2007年至2012年期间,美沙酮处方的合并过量死亡率为0.137/1000,而丁丙诺啡(包括丁丙诺啡-纳洛酮)处方的合并过量死亡率为0.022/1000。分析得出美沙酮相对于丁丙诺啡的相对风险比为6.23(95%置信区间4.79至8.10)。考虑到英国边境管理局的数据,其显示在2007年至2012年期间,进入英国领土时查获的美沙酮和丁丙诺啡数量极少,表明存在国内药物转移情况。
我们对丁丙诺啡和美沙酮用于阿片类药物替代治疗的相对安全性分析表明,就普通人群的过量用药风险而言,丁丙诺啡比美沙酮安全6倍。临床医生应意识到开具美沙酮的风险增加,需要更严格的监管以防止其转移。